Harbeck, Nadia <br/><br/>
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.  [electronic resource] 

 -  Clinical breast cancer  Dec 2004 
 - 348-52 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1526-8209 
<br/><br/><label>Standard No.: </label>10.3816/cbc.2004.n.040  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--diagnosis<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Humans<br/>Neoadjuvant Therapy<br/>Plasminogen Activator Inhibitor 1--analysis<br/>Prognosis<br/>Randomized Controlled Trials as Topic<br/>Treatment Outcome<br/>Urokinase-Type Plasminogen Activator--analysis